Press Releases

Date	Title	PDF Version
Oct 29, 2020	Alexion Reports Third Quarter 2020 Results
Oct 20, 2020	Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020
Oct 12, 2020	Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time
Oct 09, 2020	Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020
Oct 06, 2020	Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day
Sep 25, 2020	ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children
Sep 21, 2020	Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Sep 14, 2020	Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis
Sep 14, 2020	Alexion to Discuss Key Pipeline Programs at Virtual Investor Day
Sep 09, 2020	Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting

Search